Oncosil Medical (OSL) H1 2025 earnings summary

Executive summary

• Achieved significant milestones in clinical trials and commercial expansion, including new distribution agreements in the GCC, Egypt, and Nordics, and regulatory approvals in the UK and Germany.

• Completed first OncoSil treatments in leading European centers and advanced recruitment in key clinical trials for pancreatic cancer.

• Strengthened leadership with new appointments, including EMEA Sales Director and a new Non-Executive Director.

Financial highlights

• Revenue from commercial sales rose 422.2% year-over-year to $459,270 for the half-year ended 31 December 2024.

• Net loss after tax increased 11.5% year-over-year to $6,706,801.

• Cash and cash equivalents at period end were $8.47 million, up from $4.50 million at 30 June 2024.

• Received $1.05 million R&D tax incentive refund.

Outlook and guidance

• Ongoing focus on expanding commercial presence in Europe, Asia Pacific, and MENA regions.

• Continued investment in clinical trials and manufacturing capabilities, supported by recent capital raises.